Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function
Top Cited Papers
- 1 January 2008
- journal article
- Published by American Society of Hematology in Blood
- Vol. 111 (1) , 219-228
- https://doi.org/10.1182/blood-2007-04-086835
Abstract
Tumor growth induced a significant increase of myeloid-derived suppressor cells (MDSCs) in the tumor-bearing host. In our previous study, we showed that MDSCs induced tumor-specific T-cell tolerance and the development of T regulatory cells (Tregs). Tumor-derived factors have been implicated in the accumulation of MDSCs. We hypothesize that reduction of MDSC accumulation in tumor-bearing hosts, through the blockade of tumor factors, can prevent T-cell anergy and Treg development and thereby improve immune therapy for the treatment of advanced tumors. Several tumor-derived factors were identified by gene array analysis. Among the candidate factors, stem- cell factor (SCF) is expressed by various human and murine carcinomas and was selected for further study. Mice bearing tumor cells with SCF siRNA knockdown exhibited significantly reduced MDSC expansion and restored proliferative responses of tumor-infiltrating T cells. More importantly, blockade of SCF receptor (ckit)–SCF interaction by anti-ckit prevented tumor-specific T-cell anergy, Treg development, and tumor angiogenesis. Furthermore, the prevention of MDSC accumulation in conjunction with immune activation therapy showed synergistic therapeutic effect when treating mice bearing large tumors. This information supports the notion that modulation of MDSC development may be required to achieve effective immune-enhancing therapy for the treatment of advanced tumors.Keywords
This publication has 69 references indexed in Scilit:
- Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancerNature Medicine, 2007
- Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cellsJournal of Clinical Investigation, 2006
- Stem cell factor affects tumour progression markers in metastatic melanoma cellsClinical & Experimental Metastasis, 2006
- B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinomaThe Journal of Experimental Medicine, 2006
- Stem cell factor and its receptor c-Kit as targets for inflammatory diseasesEuropean Journal of Pharmacology, 2006
- Role of plasmacytoid dendritic cells in immunity and tolerance after allogeneic hematopoietic stem cell transplantationTransplant Immunology, 2003
- Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivityBlood, 2003
- Inhibition by glucocorticoids of the interleukin‐1β‐enhanced expression of the mast cell growth factor SCFBritish Journal of Pharmacology, 2002
- Early myeloid cells are high producers of nitric oxide upon CD40 plus IFN-γ stimulation through a mechanism dependent on endogenous TNF-α and IL-1αEuropean Journal of Immunology, 2000
- Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cellsNature Medicine, 1996